Germline mutations in BAP1 predispose to melanocytic tumors
Thomas Wiesner,Anna C. Obenauf,Anna C. Obenauf,Rajmohan Murali,Isabella Fried,Klaus G. Griewank,Peter Ulz,Christian Windpassinger,Werner Wackernagel,Shea Loy,Ingrid H. Wolf,Agnes Viale,Alex E. Lash,Mono Pirun,Nicholas D. Socci,Arno Rütten,Gabriele Palmedo,David H. Abramson,Kenneth Offit,Arthur Ott,Jürgen C. Becker,Lorenzo Cerroni,Heinz Kutzner,Boris C. Bastian,Michael R. Speicher +24 more
Reads0
Chats0
TLDR
Two families with a new autosomal dominant syndrome characterized by multiple, skin-colored, elevated melanocytic tumors are described, suggesting that loss of BAP1 is associated with a clinically and morphologically distinct type of melanocytics neoplasm.Abstract:
Common acquired melanocytic nevi are benign neoplasms that are composed of small, uniform melanocytes and are typically present as flat or slightly elevated pigmented lesions on the skin. We describe two families with a new autosomal dominant syndrome characterized by multiple, skin-colored, elevated melanocytic tumors. In contrast to common acquired nevi, the melanocytic neoplasms in affected family members ranged histopathologically from epithelioid nevi to atypical melanocytic proliferations that showed overlapping features with melanoma. Some affected individuals developed uveal or cutaneous melanomas. Segregating with this phenotype, we found inactivating germline mutations of BAP1, which encodes a ubiquitin carboxy-terminal hydrolase. The majority of melanocytic neoplasms lost the remaining wild-type allele of BAP1 by various somatic alterations. In addition, we found BAP1 mutations in a subset of sporadic melanocytic neoplasms showing histological similarities to the familial tumors. These findings suggest that loss of BAP1 is associated with a clinically and morphologically distinct type of melanocytic neoplasm.read more
Citations
More filters
Journal ArticleDOI
Targeting Ferroptosis to Iron Out Cancer.
TL;DR: The identification of FDA-approved drugs as ferroptosis inducers creates high expectations for the potential of ferroPTosis to be a new promising way to kill therapy-resistant cancers.
Journal ArticleDOI
BAP1 loss defines a new class of renal cell carcinoma
Samuel Peña-Llopis,Silvia Vega-Rubin-de-Celis,Silvia Vega-Rubin-de-Celis,Arnold Liao,Nan Leng,Andrea Pavia-Jimenez,Andrea Pavia-Jimenez,Shanshan Wang,Shanshan Wang,Toshinari Yamasaki,Toshinari Yamasaki,Leah Zhrebker,Leah Zhrebker,Sharanya Sivanand,Sharanya Sivanand,Patrick Spence,Patrick Spence,Lisa N. Kinch,Tina Hambuch,Suneer Jain,Yair Lotan,Vitaly Margulis,Arthur I. Sagalowsky,Pia Banerji Summerour,Wareef Kabbani,S. W Wendy Wong,Nick V. Grishin,Marc Laurent,Xian Jin Xie,Christian D. Haudenschild,Mark T. Ross,David R. Bentley,Payal Kapur,James Brugarolas +33 more
TL;DR: The results establish the foundation for an integrated pathological and molecular genetic classification of RCC, paving the way for subtype-specific treatments exploiting genetic vulnerabilities.
Journal ArticleDOI
Interplay Between the Cancer Genome and Epigenome
Hui Shen,Peter W. Laird +1 more
TL;DR: The ways in which alterations in the genome and epigenome influence each other and cooperate to promote oncogenic transformation are explored.
Journal ArticleDOI
The role of mutations in epigenetic regulators in myeloid malignancies
TL;DR: Recent genetic and functional data implicating mutations in epigenetic modifiers, including tet methylcytosine dioxygenase 2 (TET2), isocitrate dehydrogenase 1 (IDH1), IDH2, additional sex combs-like 1 (ASXL1), enhancer of zeste homologue 2 (EZH2) and DNA methyltransferase 3A (DNMT3A) are discussed.
Journal ArticleDOI
ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.
Omar Abdel-Wahab,Mazhar Adli,Lindsay M. LaFave,Jie Gao,Todd Hricik,Alan H. Shih,Suveg Pandey,Jay P. Patel,Young Rock Chung,Richard Koche,Fabiana Perna,Xinyang Zhao,Jordan E. Taylor,Christopher Y. Park,Martin Carroll,Ari Melnick,Stephen D. Nimer,Jacob D. Jaffe,Iannis Aifantis,Bradley E. Bernstein,Ross L. Levine,Ross L. Levine +21 more
TL;DR: It is identified that ASXL1 mutations result in loss of polycomb repressive complex 2 (PRC2)-mediated histone H3 lysine 27 (H3K27) tri-methylation, and that loss of AS XL1 in vivo collaborates with NRASG12D to promote myeloid leukemogenesis.
References
More filters
Journal ArticleDOI
Mutation and Cancer: Statistical Study of Retinoblastoma
TL;DR: The hypothesis is developed that retinoblastoma is a cancer caused by two mutational events, in the dominantly inherited form, one mutation is inherited via the germinal cells and the second occurs in somatic cells.
Journal ArticleDOI
SIFT: predicting amino acid changes that affect protein function
Pauline C. Ng,Steven Henikoff +1 more
TL;DR: SIFT is a program that predicts whether an amino acid substitution affects protein function so that users can prioritize substitutions for further study and can distinguish between functionally neutral and deleterious amino acid changes in mutagenesis studies and on human polymorphisms.
Journal ArticleDOI
ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage
Shuhei Matsuoka,Bryan A. Ballif,Agata Smogorzewska,Agata Smogorzewska,E. Robert McDonald,Kristen E. Hurov,Ji Luo,Corey E. Bakalarski,Zhenming Zhao,Nicole L. Solimini,Yaniv Lerenthal,Yosef Shiloh,Steven P. Gygi,Stephen J. Elledge +13 more
TL;DR: A large-scale proteomic analysis of proteins phosphorylated in response to DNA damage on consensus sites recognized by ATM and ATR is performed and more than 900 regulated phosphorylation sites encompassing over 700 proteins are identified.
PatentDOI
Genomic landscapes of human breast and colorectal cancers
Laura D. Wood,Williams D. Parsons,Sian Jones,Jimmy Lin,Tobias Sjöblom,Thomas D. Barber,Giovanni Parmigiani,Victor E. Velculescu,Kenneth W. Kinzler,Bert Vogelstein +9 more
TL;DR: Based on analysis of exons representing 20,857 transcripts from 18,191 genes, the authors concluded that the genomic landscapes of breast and colorectal cancers are composed of a handful of commonly mutated gene "mountains" and a much larger number of gene "hills" that are mutated at low frequency.
Journal ArticleDOI
Distinct Sets of Genetic Alterations in Melanoma
John A. Curtin,Jane Fridlyand,Toshiro Kageshita,Hetal N. Patel,Klaus J. Busam,Heinz Kutzner,Kwang Hyun Cho,Setsuya Aiba,Eva B. Bröcker,Philip E. LeBoit,Daniel Pinkel,Boris C. Bastian +11 more
TL;DR: The genetic alterations identified in melanoma at different sites and with different levels of sun exposure indicate that there are distinct genetic pathways in the development of melanoma and implicate CDK4 and CCND1 as independent oncogenes in melanomas without mutations in BRAF or N-RAS.
Related Papers (5)
Germline BAP1 mutations predispose to malignant mesothelioma
Joseph R. Testa,Mitchell Cheung,Jianming Pei,Jennifer E. Below,Yinfei Tan,Eleonora Sementino,Nancy J. Cox,A. Umran Dogan,A. Umran Dogan,Harvey I. Pass,Sandra Trusa,Mary Hesdorffer,Masaki Nasu,Amy Powers,Zeyana Rivera,Sabahattin Cömertpay,Mika Tanji,Giovanni Gaudino,Haining Yang,Michele Carbone +19 more
BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression
David E. Jensen,Monja L. Proctor,Sandra T. Marquis,Heather Perry Gardner,Seung I. Ha,Lewis A. Chodosh,Alexander M. Ishov,Niels Tommerup,Henrik Vissing,Yoshitaka Sekido,John D. Minna,Anna Borodovsky,David C. Schultz,Keith D. Wilkinson,Gerd G. Maul,Nickolai A. Barlev,Shelley L. Berger,George C. Prendergast,Frank J. Rauscher +18 more